Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/31125
Full metadata record
DC FieldValueLanguage
dc.contributor.authorŞişman, Pınar-
dc.date.accessioned2023-02-22T12:01:27Z-
dc.date.available2023-02-22T12:01:27Z-
dc.date.issued2020-02-03-
dc.identifier.citationŞişman, P. vd. (2020). "May hemocytometer parameters be a biomarker in distinguishing between adrenal adenomas and carcinomas and in prognosis of adrenocortical carcinomas?". Acta Clinica Croatica, 59(3), 439-444.en_US
dc.identifier.issn0353-9466-
dc.identifier.issnhttps://hrcak.srce.hr/clanak/360128-
dc.identifier.urihttps://doi.org/10.20471/acc.2020.59.03.07-
dc.identifier.urihttp://hdl.handle.net/11452/31125-
dc.description.abstractRecently, studies have reported that inflammatory response and elevated platelet counts are associated with several cancers. In the present study, we aimed to evaluate hemocytometer parameters in differentiating adrenal adenoma and carcinoma, and the prognostic utility of hemocytometer parameters in adrenocortical carcinoma (ACC). We included 30 patients with nonfunctional adrenal adenoma and 13 patients with ACC having undergone surgery between 2005 and 2017 and followed up postoperatively at our centre. The neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), red blood cell distribution width (RDW), mean platelet volume (MPV) and plateletcrit (PCT) were evaluated preoperatively in all patients included in the study. There was a significant difference between the adrenal adenoma and ACC groups in terms of neutrophil and lymphocyte counts, NLR and PLR. There was no significant difference between the two groups in terms of platelet count and MPV, but PCT levels were significantly lower in ACC group. There was no statistically significant difference between recurrent and/or metastasis positive patients and negative ones according to NLR, PLR, RDW and MPV. There was a statistically significant difference in RDW levels and tumor diameter between the groups. Our study is the first to evaluate hemocytometer parameters in differentiating adrenal adenomas and carcinomas, and also in the prognosis of ACC. The present study suggested that the hemocytometer parameters may be a marker in the differential diagnosis of adrenal adenomas and carcinomas. However, our study also showed that these parameters had no prognostic value in ACC.en_US
dc.language.isoenen_US
dc.publisherSestre Milosrdnice University Hospitalen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAdrenal adenomaen_US
dc.subjectAdrenocortical carcinomaen_US
dc.subjectHemocytometer parametersen_US
dc.subjectMean platelet volumeen_US
dc.subjectNeutrophil to lymphocyte ratioen_US
dc.subjectNeutrophil-to-lymphocyteen_US
dc.subjectManagementen_US
dc.subjectCanceren_US
dc.subjectGeneral & internal medicineen_US
dc.subject.meshAdenomaen_US
dc.subject.meshAdrenal cortex neoplasmsen_US
dc.subject.meshAdrenocortical carcinomaen_US
dc.subject.meshBiomarkersen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphocytesen_US
dc.subject.meshNeutrophilsen_US
dc.subject.meshPlatelet counten_US
dc.subject.meshPrognosisen_US
dc.titleMay hemocytometer parameters be a biomarker in distinguishing between adrenal adenomas and carcinomas and in prognosis of adrenocortical carcinomas?en_US
dc.typeArticleen_US
dc.identifier.wos000603080400007tr_TR
dc.identifier.scopus2-s2.0-85100416292tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0001-6303-7896tr_TR
dc.contributor.orcid0000-0003-4510-6282tr_TR
dc.contributor.orcid0000-0002-4127-9656tr_TR
dc.contributor.orcid0000-0003-2399-6608tr_TR
dc.identifier.startpage439tr_TR
dc.identifier.endpage444tr_TR
dc.identifier.volume59tr_TR
dc.identifier.issue3tr_TR
dc.relation.journalActa Clinica Croaticaen_US
dc.contributor.buuauthorBiçer, Buket-
dc.contributor.buuauthorGül, Özen-
dc.contributor.buuauthorCander, Soner-
dc.contributor.buuauthorErsoy, Canan-
dc.contributor.buuauthorSaraydaroğlu, Özlem-
dc.contributor.buuauthorErtürk, Erdinç-
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.researcheridAAJ-6536-2021tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.contributor.researcheridAAH-9701-2021tr_TR
dc.relation.collaborationSanayitr_TR
dc.identifier.pubmed34177053tr_TR
dc.subject.wosMedicine, general & internalen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid57220581517tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid25027068600tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.contributor.scopusid15074395500tr_TR
dc.contributor.scopusid7005488796tr_TR
dc.subject.scopusInflammation; Glasgow; Lymphocytesen_US
dc.subject.emtreeBiological markeren_US
dc.subject.emtreeAdrenal cortex adenomaen_US
dc.subject.emtreeAdrenal cortex carcinomaen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBiochemical compositionen_US
dc.subject.emtreeCancer patienten_US
dc.subject.emtreeCancer prognosisen_US
dc.subject.emtreeCancer recurrenceen_US
dc.subject.emtreeCancer sizeen_US
dc.subject.emtreeCancer surgeryen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeData analysis softwareen_US
dc.subject.emtreeDisease markeren_US
dc.subject.emtreeDistant metastasisen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHematological parametersen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman cellen_US
dc.subject.emtreeLymphocyte counten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMean platelet volumeen_US
dc.subject.emtreeNeutrophil counten_US
dc.subject.emtreeNeutrophil lymphocyte ratioen_US
dc.subject.emtreePlatelet counten_US
dc.subject.emtreePlatelet distribution widthen_US
dc.subject.emtreePlatelet lymphocyte ratioen_US
dc.subject.emtreePlateletcriten_US
dc.subject.emtreePostoperative perioden_US
dc.subject.emtreePreoperative evaluationen_US
dc.subject.emtreeRed blood cell distribution widthen_US
dc.subject.emtreeAdenomaen_US
dc.subject.emtreeAdrenal cortex carcinomaen_US
dc.subject.emtreeAdrenal cortex tumoren_US
dc.subject.emtreeLymphocyteen_US
dc.subject.emtreeNeutrophilen_US
dc.subject.emtreePrognosisen_US
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Bicer_vd_2020.pdf241.24 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons